Trailing-twelve-month (TTM) revenue is $5.65 Billion with a year-over-year growth of +9.85%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $1,335,582,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q2 FY2026Period ended 2025-12-31 | $1,422,808,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-30 |
| Q3 FY2026Period ended 2026-03-31 | $1,431,406,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q4 FY2026Period ended 2026-06-30 | $1,463,647,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $5,653,443,000 |
Current P/S: $32,274,320,158 market capitalization ÷ $5,653,443,000 TTM revenue = 5.71x.
Market capitalization source: FMP quote. Quote observed 2026-09-25T17:40:17.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $1.46B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-25T17:41:30.820Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-06-30 · USD | FY20202020-06-30 · USD | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD |
|---|---|---|---|---|---|---|
| Devices And Masks | $2.3B | $2.6B | N/A | N/A | N/A | N/A |
| Sleep And Respiratory | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-06-30 · USD | FY20192019-06-30 · USD | FY20202020-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD |
|---|---|---|---|---|---|---|
| Global | $995M | $2.6B | $3.0B | $3.6B | N/A | $1.7B |
| Sleep And Respiratory | N/A | N/A | N/A |
$5.65B
$5.65 Billion
+9.85%
vs. $5.15B a year ago (TTM)
+12.08%
5 Year compound annual growth rate
1 Year
+9.85%
3 Year
+10.21%
5 Year
+12.08%
10 Year
+11.89%
15 Year
+10.62%
20 Year
+11.80%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $5.65B | +$507.12M | +9.85% |
| 2025 | $5.15B | +$461.03M | +9.84% |
| 2024 | $4.69B | +$462.30M | +10.95% |
| 2023 | $4.22B | +$644.87M | +18.02% |
| 2022 | $3.58B | +$381.30M | +11.93% |
| 2021 |
TTM Growth
+9.85%
3-Year CAGR
+10.21%
5-Year CAGR
+12.08%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-25T17:41:30.820Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.8B |
| $3.2B |
| $3.7B |
| $4.1B |
| Software As Service | $276M | $355M | $374M | $401M | $498M | $584M |
|---|
| N/A |
| $3.7B |
| N/A |
| Software As Service | N/A | N/A | N/A | N/A | $498M | N/A |
|---|
| U [S] | $1.3B | N/A | N/A | N/A | N/A | $3.0B |
|---|
| Us Canada And Latin America | N/A | $1.7B | N/A | N/A | N/A | N/A |
|---|
| $3.20B |
| +$239.81M |
| +8.11% |
| 2020 | $2.96B | +$350.44M | +13.44% |
| 2019 | $2.61B | +$266.38M | +11.38% |
| 2018 | $2.34B | +$273.46M | +13.23% |
| 2017 | $2.07B | +$228.02M | +12.40% |
